Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma.

Journal of neuro-oncology - 1 Aug 2016

Mandel Jacob J, Cachia David, Liu Diane, Wilson Charmaine, Aldape Ken, Fuller Greg, de Groot John F

Abstract excerpt

IDH1 mutated glioblastoma (GB) has a better prognosis than IDH1 wildtype GB. However, it remains unknown whether patients (pts) with IDH1 mutated GB have a higher 6-month progression free survival (PFS6) or radiographic response (RR) rate on clinical trials for recurrence. Retrospective review of GB pts at MDACC between 2006 and 2012 identified 330 patients in recurrent GB trials. 93 patients (28 %) had either...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Brain Neoplasms
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Glioblastoma

Share to Isocitrate Dehydrogenase

Share to Neoplasm Recurrence, Local

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 27270908
DOI: 10.1007/s11060-016-2157-2
PMCID: PMC5021066

Genes

IDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma.PMID 27270908Read ↗

Accelerated progression of IDH mutant glioma after first recurrenceSemantic proximity Read ↗

Correlation between IDH1 gene mutation status and survival of patients treated for recurrent glioma.Semantic proximity Read ↗

Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status.Semantic proximity Read ↗

Do the benefits of IDH mutations in high-grade glioma persist beyond the first recurrence? A multi-institutional retrospective analysisSemantic proximity Read ↗

A Genomically Tailored Multiagent Precision Medicine Clinical Trial for Adults with Recurrent Glioblastoma.Semantic proximity Read ↗

Primary and secondary gliosarcomas: clinical, molecular and survival characteristics.Semantic proximity Read ↗

IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas.Semantic proximity Read ↗

Do Long-Term Survivor Primary Glioblastoma Patients Harbor IDH1 Mutations?Semantic proximity Read ↗

Ivosidenib, an IDH1 inhibitor, in a patient with recurrent, IDH1-mutant glioblastoma: a case report from a Phase I study.Semantic proximity Read ↗

Re-evaluating Biopsy for Recurrent Glioblastoma: A Position Statement by the Christopher Davidson Forum Investigators.Semantic proximity Read ↗

Clinical significance of histopathological features of paired recurrent gliomas: a cohort study from a single cancer center.Semantic proximity Read ↗

Genetic, Epigenetic, and Immunologic Profiling of MMR-Deficient Relapsed GlioblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.